MediGene AG Defends Dominating Patent Portfolio In The Field Of Cancer-killing Viruses (Oncolytic HSV)

Today the German-American biotech company MediGene AG (Frankfurt, TecDAX, Prime Standard: MDG) has announced that it has successfully repelled the opposition against a patent on HSV in final instance before the Boards of Appeal at the European Patent Office. The patent as maintained protects a production method for herpes simplex virus-1 vaccines including specific oncolytic herpes simplex viruses (cancer-killing HSV) developed by MediGene. The University College of London and the University Court of the University of Glasgow had opposed the patent. The two companies BioVex Ltd., and Crusade Laboratories Ltd., respectively, emerged from these two universities. MediGene had acquired an exclusive license under the patent from the University of Chicago.

Back to news